| Patents for A61K 49 - Preparations for testing in vivo (35,376) |
|---|
| 06/23/2005 | US20050136001 Fluorinated carbohydrate conjugates |
| 06/23/2005 | CA2561746A1 Methods and compounds for modulating triglyceride and vldl secretion |
| 06/23/2005 | CA2546126A1 Use of t-cadherin as a target |
| 06/22/2005 | EP1544617A2 Use of a Nifie 14 binding substance for the diagnosis and treatment of cancer |
| 06/22/2005 | EP1542733A2 Improved method to identify targeting molecules |
| 06/22/2005 | EP1542709A2 Peptide aggregates |
| 06/22/2005 | EP1414299A4 Substantially homogeneous bio-affecting material having a pre-determined ratio of bioaffecting component to cell targeting component, the method for making such a material and the method of its use |
| 06/22/2005 | EP1175392B1 Contrast media |
| 06/22/2005 | EP0973554B1 Chelating agents |
| 06/22/2005 | CN1630817A Method for sample identification in a mammal as well as a kit for performing this method |
| 06/16/2005 | WO2005054271A1 Assay for ligands of the ecdysone receptor |
| 06/16/2005 | WO2005053752A2 Novel imaging agents comprising caspase-3 inhibitors |
| 06/16/2005 | WO2005053751A1 Animal model for experimental allergic neuritis and uses thereof |
| 06/16/2005 | WO2005053643A1 Liposome |
| 06/16/2005 | WO2005053642A1 Drug delivery vehicles and uses thereof |
| 06/16/2005 | WO2005053538A2 Method |
| 06/16/2005 | WO2005044293A3 Compositions able to prevent neurodegenerative processes and methods of assaying the same |
| 06/16/2005 | WO2005037928A3 Compounds for dual photodiagnosis and therapy |
| 06/16/2005 | WO2005030266A3 Optical imaging of colorectal cancer |
| 06/16/2005 | WO2005023180A3 Method for detecting cancer cells and monitoring cancer therapy |
| 06/16/2005 | WO2005017522B1 Method for in vivo determination on tested animals of the efficient concentration of deuterium depleted water for cancer therapy |
| 06/16/2005 | WO2005007284A3 Composite nanoparticles |
| 06/16/2005 | WO2005004800A3 Trypanosome derived apoptotic factors (taf) |
| 06/16/2005 | WO2004108165A3 Magnetic nanoparticles linked to a lingand |
| 06/16/2005 | WO2003012072A3 Monoclonal antibodies to activated erbb family members and methods of use thereof |
| 06/16/2005 | US20050132448 Using streptomyces infected tubers as tools in diagnosing diabetes; macrolide antibiotic and onset of pancreatic disorders |
| 06/16/2005 | US20050132427 Monitoring cell proliferation in rodent animal model after inoculation with tumor cell line; cancer propagation and antiproliferative agents |
| 06/16/2005 | US20050131458 Biodegradable embolic agents |
| 06/16/2005 | US20050130945 Preventing recurrence of breast cancer with atamestane and toremifene |
| 06/16/2005 | US20050130127 Coronavirus-like particles comprising functionally deleted genomes |
| 06/16/2005 | US20050129727 Drug core encapsulated with multilayer polyelectrolyte shells |
| 06/16/2005 | CA2548135A1 Synthetic hla binding peptide analogues and uses thereof |
| 06/16/2005 | CA2547609A1 Assay for ligands of the ecdysone receptor |
| 06/16/2005 | CA2547236A1 Imaging agents comprising caspase-3 inhibitors |
| 06/16/2005 | CA2544890A1 Drug delivery vehicles and uses thereof |
| 06/15/2005 | EP1539990A2 PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE |
| 06/15/2005 | EP1539818A2 Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells |
| 06/15/2005 | EP1539766A1 Calcitonin gene related peptide receptor antagonists |
| 06/15/2005 | EP1539342A2 Peptide mediated synthesis of metallic and magnetic materials |
| 06/15/2005 | EP1539252A2 Blood clot-targeted nanoparticles |
| 06/15/2005 | EP1539251A2 Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis |
| 06/15/2005 | EP1539250A1 Radioactively labelled amino acid analogues, their preparation and use |
| 06/15/2005 | EP1539249A1 Procedures of cellular labelling with paramagnetic complexes for mri applications |
| 06/15/2005 | EP1539222A1 Treatment for eye disorder |
| 06/15/2005 | EP1539127A1 Method of treating osteoarthritis |
| 06/15/2005 | EP1198255A4 Identification of compounds that modify transcriptional responses to hypoxia |
| 06/15/2005 | CN1628114A Coumarines useful as biomarkers |
| 06/15/2005 | CN1627962A Non-invasive diagnostic imaging technology for mitochondria using radiolabeled lipophilic salts |
| 06/15/2005 | CN1627961A Toluidine blue O drug substance and use thereof for in VIVO Staining and chemo therapeutic treatment of dysplastic tissues |
| 06/15/2005 | CN1626246A Targeting multimeric imaging agents through multilocus binding |
| 06/14/2005 | US6906237 Vivo assay for anti angiogenic compounds |
| 06/14/2005 | US6906050 With various substitutents in the 12- and 17-positions of the porphyrin skeleton; atherosclerosis, restenosis |
| 06/14/2005 | US6905884 Fluorescent cobalamins and uses thereof |
| 06/14/2005 | US6905839 Measuring metabolic clearance for the 6 beta - hydroxylation of cortisol in subject as an index cytochrome P450 3A (CYP3A) activity without use of labeled exogenous cortisol |
| 06/14/2005 | US6905671 Using isotope of 5-aminolevulinic acid |
| 06/14/2005 | US6905670 Exposing eukaryotic organisms to a single fungal pathogen in the presence of at least one candidate compound; identifying a compound that inhibits fungal pathogen in each of eukaryotic organisms |
| 06/14/2005 | US6905668 Diagnostic agents for pancreatic exocrine function |
| 06/14/2005 | CA2175050C Liposomes and liposome vesicle precursors with porous expanded structure |
| 06/09/2005 | WO2005052186A1 Means and methods for the determination of camp in vitro and in vivo |
| 06/09/2005 | WO2005052125A2 24p3 receptors and uses thereof |
| 06/09/2005 | WO2005051435A2 Tungsten particles as x-ray contrast agents |
| 06/09/2005 | WO2005051434A1 Method for high-throughput screening of compounds and combinations of compounds for discovery and quantification of actions, particularly unanticipated therapeutic or toxic actions, in biological systems |
| 06/09/2005 | WO2005051305A2 Enhanced drug delivery |
| 06/09/2005 | WO2005051170A2 Integrated receiver for continuous analyte sensor |
| 06/09/2005 | WO2005023096A3 Methods and compositions for ultrasound imaging of apoptosis |
| 06/09/2005 | WO2005016387A3 Dna-dependent mri contrast agents |
| 06/09/2005 | US20050124695 Induction variations in central nervous system of rodents by administering kainate receptors antagonist to infant ; drug design, drug screening |
| 06/09/2005 | US20050124005 Use of a labeled ligand having human cd4 specificity for producing a diagnostic used in the analysis of migration and/or distribution patterns of cell populations |
| 06/09/2005 | US20050123981 Using gastrointestinal specific genes (GSG) as tools in detection of cell proliferative disorders; immunodiagnostics; immunohistochemistry |
| 06/09/2005 | US20050123912 Nucleoprotein for use as tool in treatment, diagnosis and prevention of infection, cell proliferative, neurological, developmental, autoimmune and inflammatory disorders |
| 06/09/2005 | US20050123909 Compositions and methods for treating cells having double minute dna |
| 06/09/2005 | US20050123563 Lipoparticles comprising proteins, methods of making, and using the same |
| 06/09/2005 | US20050123543 With an integrin linked kinase (ILK) inhibitor which can be a peptide, an antibody, an antisense agent; optionally also treating with an ACE inhibitor; ACE (Angiotensin Converting Enzyme) |
| 06/09/2005 | US20050123534 Humanised antibodies |
| 06/09/2005 | US20050123482 Temperature activated gaseous liposomes; therapy drug delivery; accumulating in cancer and disease tissue |
| 06/09/2005 | US20050123481 Radio-opaque polymeric biomaterials |
| 06/09/2005 | US20050123479 bioassays for screening antiinflammatory agents used for treating or ameliorating the symptoms of T-cell, macrophage or neutrophil mediated diseases in mammals |
| 06/09/2005 | US20050123477 Benzothiazole derivatives for in vivo imaging of amloid plaques |
| 06/09/2005 | US20050123476 Imaging the activity of extracellular protease in cells using mutant anthrax toxin protective antigens that are cleaved by specific extracellular proteases |
| 06/09/2005 | US20050123473 Diagnosis, therapy, image of celluloar disorders; antitumor agents |
| 06/09/2005 | CA2547476A1 Contrast agents |
| 06/09/2005 | CA2547456A1 Means and methods for the determination of camp in vitro and in vivo |
| 06/09/2005 | CA2546868A1 Method for high-throughput screening of compounds and combinations of compounds for discovery and quantification of actions, particularly unanticipated therapeutic or toxic actions, in biological systems |
| 06/09/2005 | CA2540621A1 Enhanced drug delivery |
| 06/08/2005 | EP1537867A1 Method of photodynamic diagnosis for vascular diseases |
| 06/08/2005 | EP1537858A1 Drug delivery vehicles and uses thereof |
| 06/08/2005 | EP1537138A2 Receptors and membrane-associated proteins |
| 06/08/2005 | EP1536842A1 Methods for functional kidney imaging using dendrimer conjugate contrast agents |
| 06/08/2005 | EP1536841A1 Monitoring and diagnosis of gastric emptying and gastroparesis |
| 06/08/2005 | EP1536834A2 Design of chemokine analogs for the treatment of human diseases |
| 06/08/2005 | EP1536818A2 Fibrinogen binding moieties |
| 06/08/2005 | EP1536770A1 Thermolabile liposome with a controlled release temperature |
| 06/08/2005 | EP1536731A2 Techniques for identifying molecular structures and treating cell types lining a body lumen using fluorescence |
| 06/08/2005 | EP1206488B1 Method for isolating and purifying grass pollen allergens |
| 06/08/2005 | EP1095064B1 Amides of hyaluronic acid and the derivatives thereof and a process for their preparation |
| 06/08/2005 | EP1003501B9 Use of an agent for lowering the risk of cardiovascular disease |
| 06/08/2005 | CN1205222C Method for isolating and purifying grass pollen allergens |
| 06/08/2005 | CN1204926C Upper digestive tract cancer primary screening general investigatio ntest solution |
| 06/07/2005 | US6902890 Method of diagnosing monitoring, staging, imaging and treating cancer |
| 06/02/2005 | WO2005049096A2 Protein and polymer conjugates as chelants with enhanced blood retention |